I have a well-established track record in basic and translational immune-oncology research in both liquid and solid tumor models, and have experience directing the clinical grade manufacture of chimeric antigen receptor T cell (CAR-T), tumor-infiltrating lymphocyte (TIL), dendritic cell vaccine, among other gene-modified effector cell products for clinical trials and pre-clinical IND development. My drive is to conduct hypothesis-based scientific research that will augment or create new cellular immunotherapies.